Divi's Laboratories — 360° view

Divi's Laboratories, a company in the Pharmaceuticals industry, reported revenue of ₹3,676 crore and net profit of ₹1,127 crore for the September 2026 quarter.

Divi's Laboratories (NSE: DIVISLAB) closed at ₹11,180.50 on 20 Nov 2026, up 73.0% over the past year. Its market capitalisation is ₹2,96,807 crore and it trades at 86.9 times earnings.

Share price
₹11,180.50 (20 Nov 2026)
Market cap
₹2,96,807 Cr (20 Nov 2026)
P/E
86.86 (20 Nov 2026)
Revenue
₹3,676 Cr (September 2026 quarter)
Net profit
₹1,127 Cr (September 2026 quarter)
ROCE
22.0% (FY26)
ROE
16.5% (FY26)
Book value
₹678 (FY26)
Dividend yield
0.27% (last 12 months to 20 Nov 2026)
52-week high / low
₹11,824.00 / ₹5,647.50 (20 Nov 2026)
1-year return
73.0% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: DIVISLAB

Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.